A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. - Wikidata - wikimedia - TriplyDB

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

http://www.wikidata.org/entity/Q36103026

about

New perspectives in glioblastoma antiangiogenic therapy Development of targeted therapies in treatment of glioblastoma Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Adaptation to antiangiogenic therapy in neurological tumors Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme Metabolic impact of anti-angiogenic agents on U87 glioma cells Perfluorocarbon nanoparticles: evolution of a multimodality and multifunctional imaging agent.Glioblastoma cell-secreted interleukin-8 induces brain endothelial cell permeability via CXCR2 αvβ8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion.Recurrent malignant gliomas.Brain neoplasms and coagulation-lessons from heterogeneity.IDH1-associated primary glioblastoma in young adults displays differential patterns of tumour and vascular morphology Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.The challenges and the promise of molecular targeted therapy in malignant gliomas.Emerging insights into the molecular and cellular basis of glioblastoma.Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth.A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma Sunitinib enhances neuronal survival in vitro via NF-κB-mediated signaling and expression of cyclooxygenase-2 and inducible nitric oxide synthase.Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression.Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab.Critical multiple angiogenic factors secreted by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies.Update on bevacizumab and other angiogenesis inhibitors for brain cancer.Current status of antiangiogenic therapies for glioblastomas.State of the art and perspectives in the treatment of glioblastoma.Silencing of epidermal growth factor, latrophilin and seven transmembrane domain-containing protein 1 (ELTD1) via siRNA-induced cell death in glioblastoma.Differential regulation of TGF-β-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma AGR2 expression is regulated by HIF-1 and contributes to growth and angiogenesis of glioblastoma.NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.Downregulation of LRIG2 expression inhibits angiogenesis of glioma via EGFR/VEGF-A pathway.Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.Localized targeted antiangiogenic drug delivery for glioblastoma.Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.

P2860

Q26746028-4ACF1103-7750-4508-B66E-4F8D8790D6E8 Q26778787-802654F1-93A9-4072-A84C-247E5A92146C Q26853516-8A9C628E-FAC7-4165-A2D1-AE45A40CD007 Q27001560-7230D432-7EA6-4BF6-8756-2CD88B9FFEA4 Q27024830-2E99736A-0D6E-4A68-807F-EB763151A162 Q28078539-F8F23CBA-7994-47B2-BB82-B71071D591ED Q28082908-7ED1D54D-0135-4C98-9BAC-BB9A4D7BD3B4 Q28087485-A135E78A-FF22-450B-8902-1772D74DC408 Q28539644-CC61F116-B0C5-4333-B710-3903BEAB394A Q30434964-625F1CE2-EB61-425F-90D3-1A32BA7B5392 Q31101680-39C7B5BD-22F7-4DB9-8905-63AF94A8CF84 Q34320583-633065DF-5DF9-4F05-AB69-43590BDC4ACA Q34438507-5BC447B9-1EB3-46B0-B828-E763DC7BEF9D Q34463432-11704BCA-15C0-49D4-95E2-B9EEDA262576 Q34602320-C4E2AB64-6668-47E0-818C-57C698254245 Q34978253-13398854-D1AF-45F3-BD22-4AF541D03955 Q35214534-B3E7EF9A-E25C-42F5-876E-A89585CF7433 Q35914897-A12E0A1E-C604-4B6B-859A-9273869736FD Q36062996-32D3276E-C157-4458-A0F8-B96F62EEF909 Q36143344-4C226E4F-ED3D-4701-AA9B-8EE7185BF920 Q36943903-B248731C-FCED-41F4-B388-0A3C5CD86409 Q37021589-A3207504-0798-4E8A-935E-92E83340F561 Q37053448-10094304-4C3D-41A3-8C84-DADDEDCE8F18 Q37218231-E9703215-9973-4CA4-9406-D7B304985575 Q38028951-0AD408E4-F8F9-44DA-9445-18629D3BBFD8 Q38066416-502AA2FE-7CA5-4842-A3E2-59882DF669B4 Q38106370-80EC42F4-84F8-401A-BBC0-C49BD9C58C87 Q38169761-0E0641E6-B857-44D5-859A-8A99E3C21667 Q38233067-639C40D0-5BF3-470A-89AD-E21B9112862F Q38759795-0B93F63F-FA5C-4E07-A56A-67A915317787 Q38962204-59A2D900-E67F-4B6F-BF12-1770BCBAA1AF Q39146753-C0899373-DC08-4A9B-A65B-BBB749BE9D97 Q39259854-3E219901-3D75-486D-AF51-E255D99EC8BA Q41701946-DF0D4BF8-DEFF-426D-A75C-8A9E03814C51 Q45069709-DFC0F86C-63A0-4A98-9D61-A01694116098 Q45070195-BB661CD1-FDD2-4D14-8937-7BA0F5DE723B Q47424261-801BEB0E-4474-4ECF-AD2F-56770111AD8F Q47736401-091A3348-486F-4F8B-90F4-9AE2FA293A2B Q48228251-02DEF2E4-50F6-4448-86C6-D050579E655D Q48865058-460FCB1F-A6A5-4906-A443-3A0AEDF6FF32

P2860

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

http://www.wikidata.org/entity/Q36103026

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

@ast

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

@en

type

label

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

@ast

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

@en

prefLabel

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

@ast

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

@en

P1433

Q36103026-5A187801-89EB-4A2F-8BFA-EA28B12FA655

P1476

Q36103026-A454C17F-BA56-4162-ADB1-B180E502DDAC

P2093

Q36103026-2ADE59C3-017D-4197-A6B5-4D41A4EE0AF6

Q36103026-2DB26BB3-6FA3-4D9E-AEC2-5910A8B4E9F8

Q36103026-560F6DCA-FDFF-4E02-A4FE-13A24402BEEC

Q36103026-72ED73A3-988C-4D8C-9165-10E008563A85

Q36103026-84F92BBD-93CE-4340-B800-346483EF485A

Q36103026-A64043D9-57BB-4CD8-8CB6-59C83F382C78

Q36103026-A72816DF-CA71-4707-A16F-20C918AF4069

P2860

Q36103026-02F5B982-B9D9-49F1-AC50-676BB5E8CDEC

Q36103026-051AE933-E3C4-457C-A397-99E2B2133D49

Q36103026-05FD3B97-CA85-4FE0-A66B-0FBC828B4ACC

Q36103026-07B6054B-BD14-41C8-B051-C2CFB6A0B9B1

Q36103026-086BF774-F16B-414E-AE48-E7B9632F756F

Q36103026-0A313D73-A279-4614-9C71-DD50C1A0200C

Q36103026-0B573989-EA69-49EE-B4C8-D1184BBFA178

Q36103026-0C1E964C-B5F6-414C-B72D-BAA7C820119A

Q36103026-0DAEF5D8-5BCC-4B25-BB57-E18B55B75869

Q36103026-0EA34441-3E52-430D-8888-8BA21878E31F

P304

Q36103026-1DE83027-9D04-4D5F-9498-89FC97F5F007

P31

Q36103026-F1311EE1-302D-4106-BC5D-BE6048E0E5C3

P356

Q36103026-5987ACCA-251C-402F-9588-75441F64B6B3

P433

Q36103026-D503259B-2D5D-454D-A95E-9387227B93DD

P478

Q36103026-0AFF6FEB-6445-40F9-AF18-615A15C16A2B

P50

Q36103026-0D5EB9B9-80C3-466A-9A0F-082738650BF0

Q36103026-13A6DA69-80EB-4EFB-A952-2597C06DE7D3

Q36103026-19207CDD-532E-4CCE-BD38-CC38F88B5445

Q36103026-19AFCD02-9A80-4455-A2E1-85C1984D438E

Q36103026-32D39B2B-8BBD-4541-8D22-85FF860F37EA

Q36103026-E5F44E52-4A19-4CCE-868E-E9AA26E85BCB

Q36103026-E97D8A8F-21F2-42A8-9D3C-EC7A82AF3026

P577

Q36103026-D1EDA761-C5E3-4AD7-B253-03A1DEA165DB

P698

Q36103026-9445DF40-9247-4D7E-8A98-E0AEC8164AA9

P932

Q36103026-3834292F-82EC-486D-84F5-ADA87E9DA036

P356

JNCCN.2011.0038

P1433

Journal of the National Comprehensive Cancer Network

P1476

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

@en

P2093

James E Herndon

http://www.w3.org/2001/XMLSchema#string

James J Vredenburgh

http://www.w3.org/2001/XMLSchema#string

John H Sampson

http://www.w3.org/2001/XMLSchema#string

John P Kirkpatrick

http://www.w3.org/2001/XMLSchema#string

Katherine B Peters

http://www.w3.org/2001/XMLSchema#string

Lee W Jones

http://www.w3.org/2001/XMLSchema#string

Scott Turner

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Modes of resistance to anti-angiogenic therapy

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization

Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

P304

414-427

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6004/JNCCN.2011.0038

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Darell D. Bigner

Henry Seth Friedman

Annick Desjardins

Sridharan Gururangan

David A Reardon

Roger E McLendon

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21464146

http://www.w3.org/2001/XMLSchema#string

P932

3399727

http://www.w3.org/2001/XMLSchema#string